{
  "_metadata": {
    "version": "2.0",
    "ticker": "EWTX",
    "asset_name": "edg7500"
  },
  "asset": {
    "name": "EDG-7500",
    "ticker": "EWTX",
    "modality": "Small molecule cardiac sarcomere modulator",
    "stage": "Phase 2",
    "one_liner": "First-in-class cardiac sarcomere modulator for HCM that slows acto-myosin engagement without inactivating myosin, avoiding the LVEF reductions seen with cardiac myosin inhibitors",
    "ownership": "Wholly-owned"
  },
  "target": {
    "name": "Cardiac Sarcomere (Acto-Myosin)",
    "full_name": "Cardiac sarcomere acto-myosin complex",
    "class": "Sarcomere modulator",
    "pathway": "Acto-myosin cross-bridge cycling → cardiac contraction → hypercontractility in HCM",
    "biology": {
      "simple_explanation": "EDG-7500 is a first-in-class selective cardiac sarcomere modulator designed to slow the rate of myocardial force generation in early systole and accelerate actin-myosin cross-bridge detachment in early diastole to improve ventricular filling. Unlike cardiac myosin inhibitors (CMIs) which stabilize the super-relaxed state by inactivating myosin, EDG-7500 preserves cardiac myosin function and does not affect myosin-actin proximity or cross-bridge reattachment rates.",
      "mechanism_vs_cmi": {
        "cmi_mechanism": "Selectively inhibit cardiac myosin ATPase activity to stabilize super-relaxed (SRX) state, decreasing myosin-actin cross-bridge formation",
        "edg7500_mechanism": "Slows rate of acto-myosin engagement and speeds disengagement WITHOUT inactivating myosin motor head",
        "key_difference": "CMIs can cause unpredictable LVEF reduction; EDG-7500 designed to preserve LVEF"
      },
      "downstream_effects": [
        "Decreased LVOT obstruction",
        "Improved diastolic filling",
        "Preserved systolic function (LVEF maintained)"
      ]
    },
    "why_good_target": {
      "clinical_validation": "Sarcomere modulation validated by mavacamten (CAMZYOS) and aficamten approval in oHCM",
      "unmet_need": [
        "CMIs cause unpredictable LVEF reduction requiring frequent echocardiogram monitoring",
        "Mavacamten requires REMS program in US with echos every 4-12 weeks",
        "Up to 13.8% of patients on mavacamten develop LVEF <50%",
        "Nonobstructive HCM (2/3 of patients) has NO approved therapies",
        "Current therapies (beta-blockers, CCBs, disopyramide) do not modify disease"
      ]
    }
  },
  "disease_background": {
    "hcm_overview": {
      "definition": "Hypertrophic cardiomyopathy (HCM) is characterized by enhanced cardiac actin-myosin cross-bridge cycling, leading to hypercontractility, myocardial hypertrophy, fibrosis, and diastolic dysfunction",
      "prevalence": "Most common inherited cardiac condition; ~1 in 500 people",
      "us_patients": "~600,000 patients in US",
      "genetics": "Traditionally considered monogenic but polygenic component increasingly recognized"
    },
    "ohcm_phenotype": {
      "definition": "Obstructive HCM - combination of hypercontractility, hypertrophy, small LV cavity, and abnormal mitral valve apparatus leading to LVOT obstruction",
      "prevalence": "2/3 of HCM patients (~200,000 US)",
      "pathophysiology": "LVOT gradient ≥30 mmHg at rest or ≥50 mmHg with provocation",
      "symptoms": "Dyspnea, chest pain, syncope, exercise intolerance, heart failure"
    },
    "nhcm_phenotype": {
      "definition": "Nonobstructive HCM - ventricular hypertrophy without significant LVOT obstruction",
      "prevalence": "1/3 of HCM patients (~400,000 US)",
      "unmet_need": "NO approved therapies; underserved population",
      "pathophysiology": "Diastolic dysfunction, impaired filling, elevated filling pressures"
    }
  },
  "current_treatment_landscape": {
    "first_line_therapy": {
      "agents": "Non-vasodilating beta-blockers (metoprolol, propranolol, nadolol)",
      "mechanism": "Decrease calcium entry, reduce heart rate, prolong diastolic filling",
      "efficacy": "Variable LVOT reduction; substantial proportion are non-responders",
      "evidence": "No adequately powered RCTs; based on long-standing clinical use and expert consensus",
      "limitations": "Do not modify disease; inconsistent efficacy"
    },
    "second_line_therapy": {
      "agents": "Non-dihydropyridine calcium channel blockers (verapamil, diltiazem)",
      "mechanism": "Inhibit L-type calcium channels, negative inotropy, prolong diastolic filling",
      "efficacy": "Variable; substantial proportion are non-responders",
      "evidence": "No adequately powered RCTs",
      "limitations": "Do not modify disease"
    },
    "third_line_therapy": {
      "agent": "Disopyramide",
      "mechanism": "Sodium channel blocker with negative inotropic effects; inhibits peak/late sodium currents, L-type calcium currents, and RyRs",
      "efficacy": "Some data showing symptomatic benefit",
      "limitations": [
        "QTc prolongation",
        "Drug-drug interactions",
        "Systemic anticholinergic symptoms",
        "Tachyphylaxis",
        "Inconsistent efficacy"
      ]
    },
    "cardiac_myosin_inhibitors": {
      "class_overview": "First drug class designed to directly target underlying pathophysiology of HCM; only HCM therapy with data from multiple placebo-controlled Phase III trials",
      "mechanism": "Selectively inhibit cardiac myosin ATPase activity to stabilize super-relaxed (SRX) state, decreasing excessive myosin-actin cross-bridge formation",
      "mavacamten": {
        "brand_name": "CAMZYOS",
        "company": "Bristol-Myers Squibb",
        "approval": "FDA approved for symptomatic oHCM (NYHA Class II-III)",
        "pivotal_trials": "EXPLORER-HCM (Phase 3), VALOR-HCM (Phase 3)",
        "efficacy_explorer": "Improved exercise capacity, reduced LVOT gradient, alleviated symptoms",
        "efficacy_valor": "Reduced need for septal reduction therapy in most patients",
        "remodeling": "Favorable LV remodeling - improved LV mass index, max wall thickness, LA volume index",
        "safety_lvef_reduction": "5.6% in EXPLORER-HCM; 8.7% in OLE; up to 13.8% in VALOR-HCM",
        "safety_severe_lvef": "2 patients with LVEF <30% and 1 death in VALOR-HCM",
        "safety_afib": "7.8-10.2% new-onset AF (higher than expected 2-3%/year)",
        "rems_required": "Yes - echo every 4 weeks initially, every 12 weeks once stable",
        "price": "$89,500/year in US"
      },
      "aficamten": {
        "company": "Cytokinetics",
        "status": "Under regulatory review for oHCM",
        "pivotal_trial": "SEQUOIA-HCM (Phase 3)",
        "differentiators": "Shorter half-life (3.4 days), no significant drug-drug interactions",
        "efficacy": "pVO2 improvement +1.74 ml/kg/min; >95% clinically meaningful improvement",
        "safety_lvef": "5.3% LVEF <50%",
        "safety_afib": "2.4% (lower than mavacamten)"
      }
    },
    "invasive_therapies": {
      "surgical_myectomy": "Preferred for surgical candidates; can address multiple pathologies; <2% mortality at high-volume centers",
      "alcohol_septal_ablation": "For non-surgical candidates; limited by coronary anatomy; up to 20% pacemaker dependence"
    }
  },
  "edg7500_differentiation": {
    "vs_cmi_mechanism": "Slows acto-myosin engagement WITHOUT inactivating myosin (CMIs inactivate myosin to stabilize SRX state)",
    "vs_cmi_lvef": "No meaningful LVEF reductions observed across development program",
    "vs_cmi_monitoring": "May not require REMS or frequent safety echocardiograms",
    "vs_cmi_indications": "Active in both oHCM AND nHCM (CMIs only approved for oHCM)",
    "preclinical_findings": "LVEF >50% maintained even at highest exposures in animal models",
    "phase_1_findings": "Well tolerated in healthy volunteers; no LVEF <50% even above therapeutic exposure; half-life ~30 hours"
  },
  "clinical_data": {
    "trial_name": "CIRRUS-HCM (Phase 2)",
    "trial_design": {
      "phase": "Phase 2",
      "design": "Multicenter open-label study of safety, tolerability, PK, and PD",
      "doses_tested": "50 mg and 100 mg",
      "data_cutoff": "May 2025 (preliminary)"
    },
    "populations": {
      "ohcm": {
        "n": 17,
        "description": "Patients with obstructive HCM"
      },
      "nhcm": {
        "n": 12,
        "description": "Patients with nonobstructive HCM"
      },
      "total": {
        "n": 29,
        "description": "Combined cohorts"
      }
    },
    "baseline_ohcm": {
      "age": "61 (13) years",
      "female": "71%",
      "nyha_ii": "59%",
      "nyha_iii": "35%",
      "lvef": "65 (4)%",
      "lvot_g_rest": "59 (30) mmHg",
      "lvot_g_valsalva": "93 (32) mmHg",
      "e_prime": "6 (2) cm/s",
      "nt_probnp_median": "710 pg/mL",
      "kccq_oss": "63 (16)",
      "kccq_css": "69 (15)",
      "sarcomere_variant": "24%"
    },
    "baseline_nhcm": {
      "age": "54 (19) years",
      "female": "58%",
      "nyha_ii": "50%",
      "nyha_iii": "50%",
      "lvef": "61 (6)%",
      "lvot_g_rest": "9 (6) mmHg",
      "e_prime": "7 (2) cm/s",
      "nt_probnp_median": "715 pg/mL",
      "kccq_oss": "57 (22)",
      "kccq_css": "63 (23)",
      "sarcomere_variant": "33%",
      "icd": "50%"
    },
    "efficacy_results": {
      "ohcm_lvot_resting_50mg_wk4": "43% <30 mmHg",
      "ohcm_lvot_resting_100mg_wk4": "89% <30 mmHg",
      "ohcm_lvot_valsalva_50mg_wk4": "57% <50 mmHg",
      "ohcm_lvot_valsalva_100mg_wk4": "89% <50 mmHg",
      "ohcm_ntprobnp_100mg": "~82% reduction; 56% achieved <150 pg/mL",
      "ohcm_e_prime_wk1": "Rapid improvement within 1 week",
      "ohcm_e_prime_100mg_wk2": "+27% (p≤0.05)",
      "ohcm_nyha_improvement_50mg": "43% ≥1 class",
      "ohcm_nyha_improvement_100mg": "78% ≥1 class",
      "ohcm_clinical_improvement": "89%",
      "nhcm_ntprobnp_50mg": "~48% reduction",
      "nhcm_ntprobnp_100mg": "~64% reduction",
      "nhcm_e_prime_wk1": "Changes as early as 1 week",
      "nhcm_clinical_improvement": "88%"
    },
    "safety": {
      "lvef_key_finding": "No LVEF <50% across broad exposure range",
      "lvef_nhcm_low_baseline": "4 patients with baseline <60% all remained stable (+2.5% change)",
      "discontinuation": "1/29 (3.4%) due to moderate dizziness",
      "dizziness": "27.6% (mostly mild/transient)",
      "upper_respiratory": "17.2%",
      "atrial_fibrillation": "13.8% (4/29) - 2 SAEs; none had LVEF <50%",
      "palpitations": "10.3%"
    }
  },
  "catalysts": [
    {
      "event": "Longer-term CIRRUS-HCM data with dose optimization",
      "timing": "2026",
      "importance": "high",
      "what_to_watch": "Durability; continued LVEF safety; optimal dosing"
    },
    {
      "event": "Phase 3 trial initiation",
      "timing": "TBD",
      "importance": "critical",
      "what_to_watch": "Trial design for oHCM and/or nHCM"
    }
  ],
  "competitive_landscape": {
    "competitors": [
      {
        "drug": "mavacamten (CAMZYOS)",
        "company": "Bristol-Myers Squibb",
        "limitation": "REMS required; LVEF <50% up to 13.8%; $89,500/year; oHCM only"
      },
      {
        "drug": "aficamten",
        "company": "Cytokinetics",
        "limitation": "LVEF <50% in 5.3%; oHCM only; will likely need monitoring"
      }
    ],
    "our_advantages": [
      "No meaningful LVEF reductions - may eliminate need for REMS/frequent echos",
      "Active in BOTH oHCM AND nHCM (2/3 of HCM has no approved treatments)",
      "Different mechanism preserves myosin function",
      "Rapid diastolic improvement (e') within 1 week",
      "89% clinical improvement oHCM; 88% nHCM"
    ]
  },
  "investment_analysis": {
    "probability_of_success": "De-risked by Phase 2; larger trials needed",
    "peak_sales_estimate": "$2-4B+ if successful in oHCM + nHCM",
    "key_risks": [
      "Small Phase 2 (N=29)",
      "CMI competitors have head start",
      "AF signal (13.8%) needs monitoring",
      "nHCM regulatory path unclear"
    ]
  },
  "market_opportunity": {
    "tam": "$2-4B (CMI class)",
    "patient_population": "600,000 US (200K oHCM, 400K nHCM)",
    "unmet_need": "nHCM has NO approved therapies; oHCM therapies have significant monitoring burden"
  }
}
